Link CJ - Search Results

1

Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing alpha(1,3)galactosyl epitopes.

Rossi GR, Unfer RC, Seregina T, Link CJ. Rossi GR, et al. Among authors: link cj. Cancer Immunol Immunother. 2005 Oct;54(10):999-1009. doi: 10.1007/s00262-005-0667-4. Epub 2005 May 12. Cancer Immunol Immunother. 2005. PMID: 15889257 Free PMC article.

2

Effective treatment of preexisting melanoma with whole cell vaccines expressing alpha(1,3)-galactosyl epitopes.

Rossi GR, Mautino MR, Unfer RC, Seregina TM, Vahanian N, Link CJ. Rossi GR, et al. Among authors: link cj. Cancer Res. 2005 Nov 15;65(22):10555-61. doi: 10.1158/0008-5472.CAN-05-0627. Cancer Res. 2005. PMID: 16288048

3

Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity.

Rossi GR, Mautino MR, Awwad DZ, Husske K, Lejukole H, Koenigsfeld M, Ramsey WJ, Vahanian N, Link CJ. Rossi GR, et al. Among authors: link cj. J Immunother. 2008 Jul-Aug;31(6):545-54. doi: 10.1097/CJI.0b013e31817d2f45. J Immunother. 2008. PMID: 18528300

4

Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy.

Unfer RC, Hellrung D, Link CJ Jr. Unfer RC, et al. Among authors: link cj jr. Cancer Res. 2003 Mar 1;63(5):987-93. Cancer Res. 2003. PMID: 12615713

5

Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.

Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. Coveler AL, et al. Immunotherapy. 2016 Feb;8(2):117-25. doi: 10.2217/imt.15.113. Epub 2016 Jan 20. Immunotherapy. 2016. PMID: 26787078 Review.

6

The αGal HyperAcute(®) Technology: enhancing immunogenicity of antiviral vaccines by exploiting the natural αGal-mediated zoonotic blockade.

Mandell RB, Flick R, Staplin WR, Kaniewski LD, Carzoli AK, Manuszak RP, Wang J, Rossi GR, Vahanian NN, Link CJ. Mandell RB, et al. Among authors: link cj. Zoonoses Public Health. 2009 Aug;56(6-7):391-406. doi: 10.1111/j.1863-2378.2008.01191.x. Zoonoses Public Health. 2009. PMID: 19486321

7

Pancreatic cancer: Update on immunotherapies and algenpantucel-L.

McCormick KA, Coveler AL, Rossi GR, Vahanian NN, Link C, Chiorean EG. McCormick KA, et al. Hum Vaccin Immunother. 2016 Mar 3;12(3):563-75. doi: 10.1080/21645515.2015.1093264. Hum Vaccin Immunother. 2016. PMID: 26619245 Free PMC article. Review.

8

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma.

Zakharia Y, McWilliams RR, Rixe O, Drabick J, Shaheen MF, Grossmann KF, Kolhe R, Pacholczyk R, Sadek R, Tennant LL, Smith CM, Kennedy EP, Link CJ Jr, Vahanian NN, Yu J, Shen SS, Brincks EL, Rossi GR, Munn D, Milhem M. Zakharia Y, et al. Among authors: link cj jr. J Immunother Cancer. 2021 Jun;9(6):e002057. doi: 10.1136/jitc-2020-002057. J Immunother Cancer. 2021. PMID: 34117113 Free PMC article. Clinical Trial.

9

Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-gamma exposure.

Radosevich TJ, Seregina T, Link CJ. Radosevich TJ, et al. Among authors: link cj. Hum Gene Ther. 2003 Dec 10;14(18):1765-75. doi: 10.1089/104303403322611773. Hum Gene Ther. 2003. PMID: 14670127

10

Eliciting hyperacute xenograft response to treat human cancer: alpha(1,3) galactosyltransferase gene therapy.

Link CJ Jr, Seregina T, Atchison R, Hall A, Muldoon R, Levy JP. Link CJ Jr, et al. Anticancer Res. 1998 Jul-Aug;18(4A):2301-8. Anticancer Res. 1998. PMID: 9703870

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

105 results

Search Page